Yongan Pharmaceutical (002365.SZ) released semi-annual results, with net profit of 43.4083 million yuan to mother, an increase of 247.39% over the previous year

According to Zhitong Finance App News, Yongan Pharmaceutical (002365.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 564 million yuan, an increase of 53.44% over the same period last year; achieved net profit attributable to shareholders of listed companies of 43.4083 million yuan, an increase of 247.39% over the same period last year; achieved net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 39,3616 million yuan, an increase of 1622.35% over the same period last year; basic earnings per share were 0.1501 yuan.

During the reporting period, the taurine business continued to gain strength, and product sales volume and sales prices both increased markedly compared to the same period last year, driving a sharp increase in the company's performance; various tasks in the health food business progressed steadily, and the development foundation was further consolidated; the creatine monohydrate business reversed early operating disadvantages, and profit levels steadily rebounded.